IL-23/IL-17轴因子在初诊Graves病患者治疗前后的变化

目的 检测IL-23/IL-17轴在Graves病(GD)患者外周血中的表达水平,以及1311I或抗甲状腺药物(ATD)治疗后的变化趋势.方法 收集初诊GD患者40例作为GD组,其中131I治疗组(20例)和ATD治疗组(20例);40例性别、年龄匹配的健康者设为对照组.使用ELISA法检测GD组治疗前后及对照组IL-17、IL-23水平.结果 ①两组比较,治疗前GD组血清IL-23、IL-17表达水平明显高于对照组(P＜0.05);②131I治疗后第6个月IL-23、IL-17的外周血水平较治疗前有明显降低(P＜0.05),仍明显高于对照组(P＜0.05).ATD组治疗前后差异无统计学意义.结论 IL-23、IL-17在初诊GD患者外周血中高表达,提示IL-23/IL-17轴可能参与Graves发病,同时放射性131 I治疗甲亢改善病情可能与IL-23/IL-17轴因子变化部分相关.

Change of IL-23/IL-17 axis in peripheral blood of patients with Graves disease treated by I or antithyroid drugs therapy

Objective To detect the expression level of interleukin-17 (IL-17)/interleukin-23 (IL-23) axis in peripheral blood of patients with Graves disease (GD) before and after 131I or antithyroid drugs (ATD) treatment.Methods The study groups included 40 patients with incipient GD(GD group),20 of whom were treated by 131 I,others were treated by ATD.Forty sex and age matched healthy subjects were recruited as control group.ELISA was uesed to detect interleukin-17 (IL-17),interleukin-23 (IL-23) level before and after the treatment of the GD group and control group.Results ① The expression of IL-23,IL-17 in GD group was significantly higher than the control group(P ＜0.05);②6 months after 131I treatment,the level of serum IL-23,IL-17 were significantly lower than before (P ＜ 0.05),but still higher than the control group (P ＜ 0.05),which was not found in ATD treatment group.Conclusion IL-23/IL-17 axis may play a role in GD which may also be relevant to 131I treatment.